Immune-boosting therapy shows promise for advanced Merkel cell carcinoma
Oct. 6, 2015
| By Dr. Rachel Tompa / Fred Hutch News Service
Skin cancer researcher Dr. Paul Nghiem is leading a clinical trial testing the immunotherapy drug pembrolizumab for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Early results from the trial are showing great promise for these patients.